Reprint
Advances in Multiple Sclerosis Research —Series I
Edited by
April 2021
334 pages
- ISBN978-3-03943-947-8 (Hardback)
- ISBN978-3-03943-948-5 (PDF)
This book is a reprint of the Special Issue Advances in Multiple Sclerosis Research—Series I that was published in
Biology & Life Sciences
Computer Science & Mathematics
Medicine & Pharmacology
Public Health & Healthcare
Summary
Designing immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Issue focused on delivery methods to be used for vaccines, immunotherapeutic approaches, drug design, and anti-inflammatories and their outcomes in preclinical studies and clinical trials.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
multiple sclerosis; inflammation; oxidative; biomarker; sample size; multiple sclerosis; autoimmune encephalitis; plasma exchange; autoimmunity; immunotherapeutics; clinical outcomes; major depression; multiple sclerosis; bupropion; S-adenosylmethionine; vitamin D3; yoga; craniopharyngioma; fractionated stereotactic radiation treatments; sphenoid sinusitis; cranial nerve-VI palsy; multiple sclerosis; autoimmune diseases; immune thrombocytopenic purpura; autoimmune encephalitis; alemtuzumab; antibodies against GluR3 peptide; multiple sclerosis; cognitive impairment; diagnosis; neuropsychological assessment; short intracortical inhibition; intracortical facilitation; fampridine; multiple sclerosis; walking disability; TSPAN32; tetraspanins; multiple sclerosis; cellular immunity; memory T cells; tDCS; neuroimaging; positron emission tomography; cerebral blood flow; multiple sclerosis; probiotics; Streptococcus thermophilus; ST285; MBP83–99 peptide; mannan; immune modulation; multiple sclerosis; agonist peptide; gut microbiome; gut–brain axis; metagenomics; multiple sclerosis; disease-modifying treatments; multiple sclerosis; MS; vaccine; immunomodulation; carriers; B cell receptor; delivery methods; immunotherapy; monoclonal antibodies; multiple sclerosis; T cell receptor; tolerance; vaccine; multiple sclerosis; diagnostic markers; immunoglobulins; kappa; free light chains; multiple sclerosis; autoimmune diseases; antigen-specific immunotherapies; tolerogenic vaccines; tolerance induction; central nervous system; myelin peptides; myelin basic protei; proteolipid protein; myelin oligodendrocyte glycoprotein; multiple sclerosis; nanotechnology; drug delivery nanosystems; lipids; polymers; vaccines; nanoparticles; antigen-specific immunotherapy; experimental autoimmune encephalomyelitis; neurodegeneration; chloroquine; EAE; dendritic cells; microglia; astrocytes; oligodendrocytes; conformational analysis; peptides; altered peptide ligands; multiple sclerosis; MS; NMR spectroscopy; NOE-constraints; molecular dynamic; trimolecular complex; experimental autoimmune encephalomyelitis; Multiple Sclerosis; early-onset; adult-onset; Human Leucocyte Antigens; immunogenetics; clinical phenotype; clinical outcome; therapeutics; Multiple Sclerosis; antibody detection; ELISA; multivalency; N-glucosylated peptide epitopes; mannan; peptide; conjugation; MOG35-55; Graphite/SiO2 electrode; voltammetry; HPLC; multiple sclerosis; immunotherapy; vaccine; multiple sclerosis; MS; vaccine; immunomodulation; carriers; MS drugs